- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06199973
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
March 13, 2024 updated by: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
The study is being conducted to evaluate the efficacy, and safety of SHR-A1811 in advanced colorectal cancer subjects.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Qianna Zhan
- Phone Number: +0518-82342973
- Email: qianna.zhan@hengrui.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 22198
- Recruiting
- Shanghai East Hospital
-
Contact:
- Jin Li, Doctor
- Phone Number: 021-38804518
- Email: siwei_bao@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Unresectable locally advanced or distant metastatic RAS/RAF wild-type colorectal cancer diagnosed histologically or cytologically;
- After treatment with oxaliplatin, 5-fluorouracil (such as 5-FU, Capecitabine) , irinotecan (DMMR/MSI-H subjects also need anti-PD-1/PD-L1 antibody treatment failure) ;
- According to the response evaluation criteria for solid tumors (RECIST 1.1) , having at least one measurable lesion, measurable lesions should not have received local treatment such as radiotherapy (lesions located within the previously treated area may also be targeted if progression is confirmed) .
- ECOG physical strength score: 0-1;
- Expected survival was ≥12 weeks;
- 24-hour urine protein ≤1.0 g d) clotting: activated partial thromboplastin time (APTT) and international standard ratio (INR )≤1.5 × ULN (for use of a stable dose of anticoagulant therapy such as LMWH or Warfarin and INR can be screened within the expected range of anticoagulant therapy) ;
- Eligible fertile patients (men and women) must agree to use a highly effective contraceptive method with their partner for at least 7 months during the trial and after the last dose; women of reproductive age must have a negative blood pregnancy test within 7 days before the first use of the study drug;
- The subjects volunteered to join the study, signed the informed consent, good compliance, with follow-up.
Exclusion Criteria:
- Subjects on systemic therapy with corticosteroid (> 10 mg daily equivalent of prednisone) or other immunosuppressive agents, except for local inflammation and the prevention of allergy and nausea and vomiting, who had undergone major surgery or severe trauma within 4 weeks prior to the first corticosteroid of the study drug, or who required elective surgery during the trial, who had undergone minor traumatic surgery, such as needle biopsy, within 7 days prior to the first dose of the study drug;
- Previous allergies to monoclonal antibody, formulation components of SHR-A1811 products, and fluorouracil medications;
- Previous antineoplastic therapy toxicities did not revert to a CTCAE v5.0 grade rating of ≤1(except for toxicities that the investigator judged to have no safety risk, such as alopecia, etc.) or the level specified by the enrollment/exclusion criteria;
- Subjects with a history of meningeal metastasis or current meningeal metastasis; active brain metastasis;
- uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;
- history of immunodeficiency, these included people who tested positive for HIV or who had a fever of > 38.5 degrees of unknown cause before the first dose (cancer fever, as judged by the researchers, could be enrolled); Severe infection (CTCAE > Grade 2) occurred within 4 weeks before the first use of the study drug, such as severe pneumonia, bacteremia, infection complications, etc. Baseline chest imaging showed active pulmonary inflammation, active hepatitis B (HBV DNA ≥500 IU/mL) and hepatitis C (HCV-RNA was higher than the lower limit of detection);
- Other malignancies in the past 5 years, not including cured skin basal-cell carcinoma and carcinoma in situ of the cervix;
- Pregnant or lactating women.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SHR-A1811
|
SHR-A1811(4.8 mg/kg) was administered intravenously on the first day of each cycle, once every 3 weeks (Q3W)
|
Experimental: physician choiced treatment
include: TAS-102, or Regorafenib, or Fruquintinib
|
physician choiced treatment,include: TAS-102(35 mg/m2, maximum 80 mg per dose), twice daily (BID) , once every 4 weeks (Q4W) , up to 3 years; or Regorafenib 160mg, once daily (QD) , once every 4 weeks (Q4W) , up to 3 years; or Fruquintinib 5mg once daily (QD) , once every 4 weeks (Q4W) , up to 3 years.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progressive free survive assessed by Independent Review Committee
Time Frame: Every 6 weeks, up to 3 years
|
Every 6 weeks, up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Security: adverse events
Time Frame: The first day of each cycle(21 days or 28 days)
|
The first day of each cycle(21 days or 28 days)
|
Effectiveness: progressive free survive assessed by the researchers
Time Frame: Every 6 weeks, up to 3 years
|
Every 6 weeks, up to 3 years
|
Effectiveness: objective response rate assessed by the researchers
Time Frame: Every 6 weeks, up to 3 years
|
Every 6 weeks, up to 3 years
|
Effectiveness: duration of response assessed by the researchers
Time Frame: Every 6 weeks, up to 3 years
|
Every 6 weeks, up to 3 years
|
Effectiveness: overall survive assessed by the researchers
Time Frame: Every 6 weeks, up to 3 years
|
Every 6 weeks, up to 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2024
Primary Completion (Estimated)
April 1, 2026
Study Completion (Estimated)
June 1, 2026
Study Registration Dates
First Submitted
December 26, 2023
First Submitted That Met QC Criteria
January 8, 2024
First Posted (Actual)
January 10, 2024
Study Record Updates
Last Update Posted (Actual)
March 15, 2024
Last Update Submitted That Met QC Criteria
March 13, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR-A1811-309
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Colorectal Cancer
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
University Health Network, TorontoRecruitingAdvanced Breast Cancer | Advanced Colorectal Cancer | Cancer RehabilitationCanada
-
Haihe Biopharma Co., Ltd.UnknownAdvanced Solid Tumor | Advanced/Metastatic Colorectal CancerChina
-
University of ChicagoVerastem, Inc.RecruitingColorectal Cancer | Colorectal Cancer Metastatic | Colorectal Adenocarcinoma | Advanced Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
-
Sun Yat-sen UniversityActive, not recruitingDMMR Colorectal Cancer | MSI-H Colorectal Cancer | Locally Advanced Colorectal CancerChina
-
Holy Stone Healthcare Co., LtdCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Colorectal Cancer (mCRC)United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors | Locally Advanced or Metastatic Breast or Colorectal CancerUnited States
-
Mirati Therapeutics Inc.Active, not recruitingMetastatic Colorectal Cancer | Advanced Colorectal CancerUnited States, Denmark, Finland, Italy, Spain, Belgium, Romania, Taiwan, Thailand, France, Germany, Korea, Republic of, China, Malaysia, Hong Kong, Australia, Austria, Puerto Rico, Singapore, Canada, Portugal, Poland, Greece, United Kingdom and more
Clinical Trials on SHR-A1811
-
Henan Cancer HospitalRecruitingHER2 Low Breast CarcinomaChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Non-small Cell Lung CancerChina
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Non-small Cell Lung CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Atridia Pty Ltd.RecruitingAdvanced Solid TumorsChina, Korea, Republic of, Taiwan, United States, Australia
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingGastric Cancer | Colorectal CancerChina
-
Fudan UniversityRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingHER2-expressing Advanced Solid TumorsChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Solid TumorsChina